Immunomedics, Inc. (NASDAQ:IMMU)‘s stock had its “buy” rating restated by Jefferies Group LLC in a research report issued to clients and investors on Friday. They presently have a $11.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 21.55% from the stock’s current price.

Several other research firms have also weighed in on IMMU. ValuEngine raised Immunomedics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research lowered Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday. Cowen and Company initiated coverage on Immunomedics in a research report on Friday, May 26th. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company upgraded Immunomedics from a “market perform” rating to an “outperform” rating in a research note on Friday, May 5th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $10.25.

Immunomedics (NASDAQ IMMU) traded down 0.33% during midday trading on Friday, hitting $9.05. The stock had a trading volume of 2,115,453 shares. The firm’s market capitalization is $991.92 million. Immunomedics has a 1-year low of $2.02 and a 1-year high of $9.28. The firm has a 50-day moving average price of $7.84 and a 200-day moving average price of $5.80.

WARNING: “Jefferies Group LLC Reaffirms “Buy” Rating for Immunomedics, Inc. (IMMU)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/07/15/jefferies-group-llc-reaffirms-buy-rating-for-immunomedics-inc-immu.html.

Several hedge funds and other institutional investors have recently modified their holdings of IMMU. Redmile Group LLC acquired a new position in shares of Immunomedics during the first quarter valued at approximately $21,874,000. State Street Corp increased its position in shares of Immunomedics by 118.2% in the first quarter. State Street Corp now owns 3,513,549 shares of the biopharmaceutical company’s stock valued at $22,730,000 after buying an additional 1,903,355 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Immunomedics by 1,648.0% in the first quarter. Point72 Asset Management L.P. now owns 1,195,613 shares of the biopharmaceutical company’s stock valued at $7,736,000 after buying an additional 1,127,213 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new position in shares of Immunomedics during the first quarter valued at approximately $3,300,000. Finally, Vanguard Group Inc. increased its position in shares of Immunomedics by 11.9% in the first quarter. Vanguard Group Inc. now owns 4,416,533 shares of the biopharmaceutical company’s stock valued at $28,574,000 after buying an additional 468,314 shares in the last quarter. Institutional investors own 62.02% of the company’s stock.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.